Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
04:00pm, Friday, 24'th Mar 2023
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough
02:17pm, Friday, 24'th Mar 2023
Regeneron is scaling new highs after a lung disease breakthrough and analyst upgrade. The post Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough appeared first on Investor's Busines
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
12:43pm, Friday, 24'th Mar 2023 Benzinga
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial eva
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
12:33pm, Friday, 24'th Mar 2023
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Wall Street Has High Hopes for These 2 Nasdaq Stocks
12:02pm, Friday, 24'th Mar 2023
Markets were volatile early Friday. Regeneron got an analyst upgrade after releasing good news about a COPD treatment.
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
12:00pm, Friday, 24'th Mar 2023 Zacks Investment Research
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
11:12am, Friday, 24'th Mar 2023 Benzinga
Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. Contagion fears have continued to weigh on banking stocks in
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
09:12am, Friday, 24'th Mar 2023
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?
07:04am, Friday, 24'th Mar 2023 Zacks Investment Research
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?
04:36am, Friday, 24'th Mar 2023
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
Regeneron's Dupixent shows promise as COPD treatment
06:37pm, Thursday, 23'rd Mar 2023
CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
05:39pm, Thursday, 23'rd Mar 2023 Zacks Investment Research
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
Coinbase’s stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move
04:55pm, Thursday, 23'rd Mar 2023 MarketWatch
Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.
Why Shares of Regeneron Are Rising Thursday
04:08pm, Thursday, 23'rd Mar 2023 The Motley Fool
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
02:31pm, Thursday, 23'rd Mar 2023
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
